The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...

The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...

Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). The FDA first announced two months ago that any shortage of the medications ...

Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...

Credit: Eli Lilly. Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). Compounding pharmacies must now cease producing the lucrative ...

Hims & Hers stock took a hit today after the FDA ruled no shortage of tirzepatide, impacting their compounded GLP-1 drug offerings. Despite the setback, Hims & Hers' CEO will likely remain defiant ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...